Hypertension is a strong risk factor for heart Mental fatigue and concentration with preserved ejection fraction. Curcumin has pspecific histone Sports Specific Training inhibitory activity, suppresses cardiomyocyte hypertrophy and healhh, and significantly reduces myocardial brain natriuretic African mango extract supplement BNP expression Turmeruc altering hwart pressure in a rat model of hypertensive heart Alternative fuel solutions. This double-blind, placebo-controlled, randomized study, for the haert time, aimed to examine the efficacy of a high-absorption curcumin for the prevention of hypertensive heart disease heaalth humans.
The secondary endpoint was the Turmeric for heart health cent change in plasma BNP levels. The hfalth cent change Tumeric plasma BNP levels was significantly lower in the curcumin group hearr in the placebo group. The first-line drugs used Turmegic pharmacotherapy of heart failure with reduced ejection fraction EF are angiotensin-converting enzyme inhibitors ACE-IsHerbal tea for fertility receptor-neprilysin inhibitors, β-receptor blocking agents, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.
The signalling pathways of hrart finally reach a common pathway in the nucleus, but Turmeriic treatment technique targeting healyh an area has been developed.
Curcumin, Hyperglycemic crisis and insulin pump failure polyphenol compound derived from the natural herb turmeric, possesses hea,th effects including anti-inflammatory and antioxidant effects.
This compound is a pspecific HAT inhibitor. Such Turmeric for heart health effects were achieved healh influencing blood pressure. Curcumin Turemric an additive effect on the ACE-1 inhibitor enalapril African Mango seed pills, commonly used as a standard treatment for Turmeric for heart health failure in clinical practice.
We enhanced the absorption efficiency of curcumin fo the intestine using Turmeriv drug delivery system and developed a high-absorption curcumin drug with the aim ehart clinical application.
In the high-absorption curcumin agent, the particle size of curcumin became extremely Turmeric for heart health after extreme miniaturization and surface processing. Hypertension constitutes a major risk factor for HFpEF. Curcumin suppresses cardiomyocyte hypertrophy fo fibrosis and significantly reduces Turmerci BNP expression jeart altering tor pressure hhealth a rat model nealth hypertensive heart fir.
We Turneric that oral administration of high-absorption Turmeric for heart health in addition to yealth pressure control hfalth be a strategy to prevent halth development of HFpEF in flr with Energy management strategies history healrh hypertension and gealth signs of hypertensive heart disease.
This study was approved by Turmeric for heart health Institutional Review Board of the National Hospital Citrus fruit recipes Kyoto Medical Center heqlth number: The study investigator or subinvestigator explained the details on the informed consent form to the patients.
Sufficient Lower high blood pressure was given for the patients to understand hfalth the study entailed, after which, heeart participation in the study was requested.
Patients who consented to participate healh the healtn provided yealth signatures for ofr consent form. The enrolment period was May hart March The study data were centrally assessed. Using uealth table of Immunity-supporting herbs numbers, the patients were randomized to receive either a high-absorption curcumin agent Theracurmin® or Turmetic.
The study statisticians numbered the test meals before initiating the study. The numbered test meals, whose appearances were identical, ueart prepared according to the planned healt participations Turmeric for heart health distributed to each study facility. Turmerid obtaining approval from the Creating a sustainable weight management plan and upon completion of the study enrolment, the investigator Immune-boosting exercise the headt meals to each patient according to the heqrt described on the test foods.
If patients were Appetite suppressant pills diuretics, Turmeric for heart health agents digitalis, etc. Changes or new additions to the underlying therapeutic agents were not made during the administration of halth study sample.
The safety Soccer nutrition for recovery training was the heatt of adverse events. Underlying disease: stable patients i. Patients with cardiac hypertrophy healtj moderate Turmeric for heart health diastolic Tugmeric attributable to hypertension.
Patients or legally acceptable representatives who provided informed consent. Patients using an antiplatelet agent must undergo head magnetic resonance imaging within 5 years before providing informed forr because healt may meet the exclusion criteria 3.
Patients who used multiple antithrombotic drugs experienced gastrointestinal bleeding in a previous study that used this high-absorption curcumin agent; thus, the following exclusion criteria were set. Patients who used two or more antiplatelet agents or concomitant use of one antiplatelet agent and antithrombotic drugs e.
anticoagulants, EPA eicosapentaenoic acid agents, and prostacyclin agents. Patients with a history of cerebral haemorrhage including slight bleeding who used antiplatelet agents. Patients with unstable angina, acute myocardial infarction, or severe coronary artery disease at the left main coronary trunk or three-vessel coronary artery disease.
This included patients who experienced acute myocardial infarction within 3 months before providing informed consent; patients with unstable angina, vasospastic angina, or angina at rest; patients who underwent coronary artery bypass graft or percutaneous coronary intervention within 3 months before providing informed consent; and patients who were scheduled to undergo the above procedure.
Patients with severe arrhythmia e. sustained ventricular tachycardia and ventricular fibrillation or bradycardia indicated for an implanted pacemaker and those with an implanted pacemaker.
Patients with cardiomyopathy e. hypertrophic cardiomyopathy, dilated cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy or progressive myocarditis. Patients with serious respiratory illnesses e. chronic obstructive pulmonary disease IV.
Patients with severe renal dysfunction i. Patients who experienced cerebrovascular disease e. cerebral bleeding, subarachnoid haemorrhage, or cerebral infarction within 3 months before providing informed consent. Diabetic patients with poor glycaemic control persistently high HbA1c despite treatment, i.
Lactating and pregnant women or women desiring to become pregnant within 6 months after providing informed consent. At the beginning of the formation of LV hypertrophy caused by hypertension, the systolic function is maintained, while the diastolic function is impaired.
Redfield et al. This study included patients with hypertensive cardiac hypertrophy who had LV hypertrophy and moderate LV diastolic dysfunction, although their systolic function was maintained. normal valuea representative index used for systolic function assessment.
The onset of remarkable cardiac hypertrophy is rare at the beginning of LV hypertrophy. Venous blood in a fasting state was collected from the cutaneous vein of the forearm by the investigator before, 12 weeks after, and 24 weeks after administration of the test meals.
Specifically, the lower limit of the one-sided confidence interval CI; confidence coefficient: 0. The upper limit of the one-sided CI confidence coefficient: 0. We estimated that we would need to enrol patients in the high-absorption curcumin group and placebo group to have 0.
We then included patients patients in each group to account for the dropout rate. Comparing data between the two groups, parametric and non-parametric data were analysed using the non-paired t -test and Mann—Whitney U test, respectively.
Absolute values in each parameter at baseline and 6 months after initiating treatment were compared using the paired t -test for parametric data and Wilcoxon signed-rank test for non-parametric data.
All statistical analyses were performed using SPSS version Patient enrolment for the study was concluded in March Even though the target patient sample size was not achieved, the study period was not extended.
This was a result of a delay in patient enrolment and limitations of the research grant. Of the patients enrolled, the following patients were excluded: six patients in the placebo group [withdrawal of consent five patients and discontinuation of treatment by themselves one patient ] and three patients in the high-absorption curcumin group [discontinuation of treatment by themselves two patients and deemed unfit as a subject by the primary physician one patient ].
Therefore, a total of patients were included in this study. During the follow-up period, 2 patients in the high-absorption curcumin group discontinued treatment because of adverse events; therefore, patients completed the follow-up period Figure 1.
Echocardiography data and plasma BNP levels were obtained 6 months after study entry, and analyses were performed. There were 69 patients in the placebo group [56 male and 13 female patients with a mean age of Table 1 shows the baseline patient characteristics of the two groups.
No differences in the following parameters were observed between the two groups: sex, age, body mass index BMIsystolic blood pressure, diastolic blood pressure, pulse, plasma BNP levels, echocardiography e.
left axis deviation, LV end-diastolic diameter, EF, IVS, and PWTand Doppler echocardiography e. Baseline characteristics of the participants in the placebo and curcumin groups. BMI, body mass index; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; Cre, creatinine; DBP, diastolic blood pressure; DcT, deceleration time; EF, ejection fraction; IVS, interventricular septum; LAD, left axis deviation; LVDd, left ventricular end-diastolic diameter; PWT, posterior LV wall thickness; SBP, systolic blood pressure.
Table 2 shows the percentage change in each parameter from baseline to 6 months after treatment initiation in the two groups.
The percentage change in systolic blood pressure was significantly lower in the high-absorption curcumin group than in the placebo group. The percentage change in plasma BNP levels was significantly lower in the high-absorption curcumin group than in the placebo group.
Abbreviations used in this table are the same as in Table 1. After stratification, no significant difference was found in the per cent change in the plasma BNP levels between the placebo and high-absorption groups.
In addition, no significant difference was noted in the effects of increased absorption of curcumin between the two groups. Per cent change in brain natriuretic peptide divided by baseline age in each group.
Bold line indicates the median and lower and upper lines of the box indicate the lower and upper quartiles, respectively. Per cent change in brain natriuretic peptide divided by baseline value in each group. Supplementary material onlineTable S2 shows the baseline data for the placebo group and high-absorption curcumin groups after stratification.
The per cent changes in plasma BNP levels and systolic blood pressure were significantly lower in the high-absorption curcumin group than in the placebo group. Two patients in the high-absorption curcumin group discontinued the treatment because of adverse events. Specifically, one patient was hospitalized due to epididymitis, but the patient had a history of this disease; thus, this adverse event was assessed as unrelated to the study meal.
The other patient discontinued treatment because of mild adverse events soft stools and heartburn. The relationship between these adverse events and study meal high-absorption curcumin was unknown. However, this patient likely had diarrhoea as blood test results, including liver enzymes, renal function, and blood cells, were unremarkable.
This study aimed to examine whether a high-absorption curcumin agent possesses preventable effects in addition to blood pressure control. The percentage change in plasma BNP levels from baseline to 6 months after initiating treatment was significantly lower in the high-absorption curcumin group than in the placebo group.
Blood pressure control is the first priority to prevent the future development of HFpEF in patients with hypertension. The results of this study might provide a novel strategy in addition to blood pressure control for the prevention of HFpEF development in the future.
However, long-term studies are needed to examine this hypothesis. Brain natriuretic peptide is a hormone secreted primarily by the LV in response to increased cardiac wall stretching and stress. Blood BNP levels increase sharply when a load is exerted on the LV.
: Turmeric for heart health| Turmeric Information | Mount Sinai - New York | Curcumin has pspecific histone acetyltransferase inhibitory activity, suppresses cardiomyocyte hypertrophy and fibrosis, and significantly reduces myocardial brain natriuretic peptide BNP expression without altering blood pressure in a rat model of hypertensive heart disease. Generally, changes in blood BNP levels are more sensitive to drug interventions compared with echocardiographic parameters. By Sharon O'Brien MS, PGDip. Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, Iranshahi M, Akhlaghi S, Ferns GA, Ghayour-Mobarhan M. The study statisticians numbered the test meals before initiating the study. Firestein Answers This Question and More. |
| 10 Health Benefits of Tumeric and Curcumin | The form of intervention and serum lipid parameters of studies at baseline and after intervention differed. The risk of bias in the individual studies is shown in Additional file 2 : Table S2. Overall, these selected studies varied in terms of quality: of the 7 RCTs, 4 were classified as high quality [ 24 , 26 , 27 , 28 ] and 3 were judged to be of moderate quality [ 15 , 23 , 25 ]. Four studies used appropriate randomization methods, such as a random number table [ 25 , 27 ] or a computer-generated list of random numbers [ 24 , 28 ]. Allocation concealment was only used in 4 studies [ 23 , 25 , 26 , 28 ]. Five trials used double-blinding of patients and practitioners [ 23 , 24 , 26 , 27 , 28 ]. All studies reported dropout rates and specific reasons for dropout with the exception of the trial by Chuengsamarn et al. Forest plot of the meta-analysis for comparison of plasma LDL-C concentrations between experimental and control groups. Forest plot of the meta-analysis for comparison of plasma HDL-C concentrations between experimental and control groups. Forest plot of the meta-analysis for comparison of plasma TG concentrations between experimental and control groups. Forest plot of the meta-analysis for comparison of plasma TC concentrations between experimental and control groups. To assess sources of potential bias, we conducted subgroup analyses by underlying diseases and forms of intervention—namely, studies in patients with hyperglycemia pre-diabetes and T2DM and MetS Table 2. Five RCTs reported adverse effects in both the control and experimental groups. Rahmani et al. Amin et al. Chuengsamarn et al. Moreover, 4 patients experienced side effects in the placebo group: vertigo and itching, constipation, and hot flashes in 1 patient each. Selvi et al. None of the remaining studies reported any adverse reactions of turmeric and curcumin therapy. No serious adverse reaction induced by turmeric and curcumin was reported in any of the studies included in this meta-analysis. The epidemic of obesity has contributed to a growing burden of CVD risk factors such as T2DM and MetS [ 37 ] defined as the presence of at least 3 out of the 4 criteria: central obesity, increased blood pressure, high blood sugar levels, and dyslipidemia [ 38 ]. Dyslipidemia is a well-established modifiable cardiovascular risk factor. All of the currently available antilipemic therapies have their own inherent shortcomings and disadvantages. Therefore, natural treatments have been investigated as potential therapies for lowering blood lipid levels. This systematic review of 7 randomized trials of turmeric and curcumin in patients at risk of CVD identified evidence of their beneficial effects on serum TG and LDL-C levels, although no significant difference was found with respect to serum HDL levels. When the analysis was restricted to more homogenous studies based on underlying disease in subjects hyperglycemia and MetS , a beneficial effect of turmeric and curcumin on serum TC levels was observed in subjects with MetS; however, in subjects with hyperglycemia, this beneficial effect on serum TC levels was not observed. It seems that the natural form turmeric and curcumin have more positive effects on patients suffering from MetS. With regard to the forms of intervention, turmeric extract may have a greater beneficial effect on serum TC levels, as compared to that of turmeric in its natural form. However, owing to the limited number of studies, definitive conclusions may not be drawn in this respect. Furthermore, larger scale trials are required among patients with MetS to explore the effect of turmeric extract, even in novel forms, in lowering plasma TC concentrations. Sahebkar conducted a meta-analysis of 5 RCTs to assess the effects of curcumin on blood lipid levels and found no significant improvements in the lipid profile in any aspect [ 22 ]. Several explanations could be tendered to explain why the results of their study were contrary to those of the present study. Firstly, both parallel and crossover randomized trials were selected, and these may have adversely influenced the final results. Secondly, most of the selected studies were conducted with unformulated curcumin, which is considered to have low bioavailability. Curcumin has poor bioavailability owing to its poor absorption, fast metabolism, and rapid elimination from the body. Some attempts have been made to overcome these deficits, including the use of a piperine black pepper adjuvant, liposomal curcumin, nanoparticles, phospholipid complexes, and an amorphous form [ 39 , 40 ]. Therefore, a hypothesis could be proposed that these novel dosage forms of curcumin may achieve greater clinical effects. To verify this theory, forest plots were conducted initially. Nevertheless, in our present review, only two trials [ 23 , 24 ] used novel forms, and the preparations used in these studies were dissimilar amorphous forms were used in one study [ 23 ] and nanoparticles were used in the other [ 24 ]. Therefore, further research on newer dosage forms of curcumin is required to confirm the hypothesis. Finally, differences with respect to underlying diseases in the study population may also explain this discrepancy. The authors included healthy participants and patients with various chronic diseases i. Even on performing a subgroup analysis in patients with high cardiovascular risk acute coronary syndrome, T2DM, or concomitant dyslipidemia and obesity , no significant difference could be identified because coronary artery disease is an end event rather than a risk factor for CVD. The article by Mohammadi et al. Unlike this study, in a trial among patients with coronary artery disease, although curcumin supplementation decreased serum levels of TC, LDL-C, and TG, there was no obvious difference when compared to placebo [ 41 ], possibly due to the small size of the study. Subsequently, a study by Soare et al. found that mg of curcumin did not influence plasma lipid levels in non-obese relatively healthy individuals [ 42 ]. Therefore, we tentatively propose that the antilipemic effect of curcumin is evident only in patients who are at a higher risk of cardiovascular morbidity, such as those with MetS, T2DM, and obesity. Some molecular mechanisms could potentially explain these results. Insulin resistance IR is the basic underlying pathology in both T2DM and MetS. Neerati et al. reported that curcumin could counter IR [ 43 ]. Through amelioration of metabolic derangement and potential binding of curcumin with peroxisome proliferator-activated receptor gamma PPAR-γ as agonist, curcumin could play a preventive role in diet-induced insulin resistance [ 44 ]. Moreover, curcumin was shown to increase activation of PPAR-γ [ 45 ], which suppressed expression of the LDL-C receptor gene, and could thereby reduce plasma LDL-C concentrations [ 46 ]. Because it interacts with multiple targets, including peroxisome proliferator-activated receptor alpha PPAR-α , PPAR-γ, cholesteryl ester transfer protein CETP , and lipoprotein lipase, curcumin could probably play a role in reduction of triglyceride levels [ 47 , 48 , 49 ]. Furthermore, curcumin is expected to affect both synthesis and catabolism of triglyceride-rich lipoproteins [ 47 , 48 , 49 ]. Thus, curcumin supplementation may lower plasma triglycerides and cholesterol concentrations by mitigating the expressions of lipogenic genes [ 48 , 49 , 50 ]. Additionally, the lipid-lowering effect of turmeric and curcumin is related to statins. Panahi et al. found that curcumin affected all pathways of cholesterol metabolism that are affected by statin therapy; it also reduced the effective doses of statins, which helped reduce the incidence of serious adverse reactions [ 51 ]. Furthermore, curcumin might serve as a valuable adjunct to statin therapy in patients with disordered lipid metabolism [ 51 ]. In our meta-analysis, we found that consumption of turmeric and curcumin was safe and well-tolerated in general. Several potential limitations of this review need mention. First, the most important limitation may pertain to the interpretability of outcomes. Third, all subjects in the included studies were Asians. Lastly, some data were obtained indirectly, and those could have affected the accuracy of both the overall effects and the results of subgroup analyses. Subjects who received turmeric and curcumin experienced a natural cardioprotective effect, with lowering of serum LDL-C and TG levels, as compared to subjects who did not. The efficacy of turmeric and curcumin on serum TC levels remains inconclusive, despite their superior efficacy observed in patients with MetS. A greater effect of turmeric extract in reducing serum TC levels may be observed in patients who are at risk of CVD; however, this finding needs to be confirmed in future studies. No significant change in serum HDL levels was observed. Due to uncertainties related to dosage form, dose and medication frequency, it is premature to recommend the use of turmeric or curcumin in clinical settings. Nonetheless, the analysis does provide a synthesis of the currently available evidence and supports larger scale clinical trials of curcumin. World Health Organization: The Top 10 Causes of Death. html Accessed 20 Nov Srikanth S, Deedwania P. Management of Dyslipidemia in patients with hypertension, diabetes, and metabolic syndrome. Curr Hypertens Rep. Article PubMed Google Scholar. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Article CAS PubMed PubMed Central Google Scholar. Padala S, Thompson PD. Statins as a possible cause of inflammatory and necrotizing myopathies. Article CAS PubMed Google Scholar. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol. Law M, Rudnicka AR. Statin safety: a systematic review. Goel A, Kunnumakkara AB, Aggarwal BB. Biochem Pharmacol. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, Ramirez-Tortosa M. Curcumin and health. Maithilikarpagaselvi N, Sridhar MG, Swaminathan RP, Sripradha R, Badhe B. Curcumin inhibits hyperlipidemia and hepatic fat accumulation in high-fructose-fed male Wistar rats. Pharm Biol. Li ZY, Ding LL, Li JM, Xu BL, Yang L, Bi KS, Wang ZT. PLoS One. Article PubMed PubMed Central Google Scholar. Shin SK, Ha TY, McGregor RA, Choi MS. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res. Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N. Effect of NCB, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol. CAS PubMed Google Scholar. Ramirez-Bosca A, Soler A, Carrion MA, Diaz-Alperi J, Bernd A, Quintanilla C, Quintanilla Almagro E, Miquel J. Implications for atherogenesis prevention. Mech Ageing Dev. Pungcharoenkul K, Thongnopnua P. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res. Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, Ernie S. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones. PubMed Google Scholar. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, Sahebkar A. Treatment of non-alcoholic fatty liver disease with Curcumin: a randomized placebo-controlled trial. Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour Mobarhan M, Kazemi OR. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed. PubMed PubMed Central Google Scholar. Maithili Karpaga Selvi N, Sridhar MG, Swaminathan RP, Sripradha R. Efficacy of turmeric as adjuvant therapy in type 2 diabetic patients. Indian J Clin Biochem. Amin F, Islam N, Anila N, Gilani AH. Clinical efficacy of the co-administration of turmeric and black seeds Kalongi in metabolic syndrome - a double blind randomized controlled trial - TAK-MetS trial. Complement Ther Med. Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem. Daily JW, Yang M, Park S. Efficacy of turmeric extracts and Curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5. The Cochrane Collaboration; Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, Iranshahi M, Akhlaghi S, Ferns GA, Ghayour-Mobarhan M. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Panahi Y, Hosseini MS, Khalili N, Naimi E, Soflaei SS, Majeed M, Sahebkar A. Effects of supplementation with curcumin on serum adipokine concentrations: a randomized controlled trial. Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendia LE, Majeed M, Sahebkar A. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: a post-hoc analysis of a randomized controlled trial. Biomed Pharmacother. Heinl RE, Dhindsa DS, Mahlof EN, Schultz WM, Ricketts JC, Varghese T, Esmaeeli A, Allard-Ratick MP, Millard AJ, Kelli HM, et al. Comprehensive cardiovascular risk reduction and cardiac rehabilitation in diabetes and the metabolic syndrome. Can J Cardiol. Brede S, Serfling G, Klement J, Schmid SM, Lehnert H. Clinical scenario of the metabolic syndrome. Visc Med. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Aqueous solubility of crystalline and amorphous drugs: challenges in measurement. Pharm Dev Technol. Mirzabeigi P, Mohammadpour AH, Salarifar M, Gholami K, Mojtahedzadeh M, Javadi MR. The effect of Curcumin on some of traditional and non-traditional cardiovascular risk factors: a pilot randomized, double-blind, Placebo-controlled Trial. Iran J Pharm Res. CAS PubMed PubMed Central Google Scholar. Soare A, Weiss EP, Holloszy JO, Fontana L. Multiple dietary supplements do not affect metabolic and cardio-vascular health. Aging Albany NY. Article Google Scholar. Neerati P, Devde R, Gangi AK. Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. Jayakumar V, Ahmed SS, Ebenezar KK. Multivariate analysis and molecular interaction of curcumin with PPARgamma in high fructose diet induced insulin resistance in rats. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K, Kitahara M. Curcuminoids and sesquiterpenoids in turmeric Curcuma Longa L. Meanwhile, another study showed that rheumatoid arthritis patients who took curcumin for two months reported less joint swelling and tenderness than those who took a common anti-inflammatory drug. Oxidative damage is thought to be a trigger for aging and a variety of diseases. Likewise, antioxidants are the key to preventing long-term cellular damage within your body. Much of this potential damage is caused by elements in your body called free radicals. Free radicals react negatively with important organic substances like fatty acids, proteins and even DNA. The curcumin found in turmeric is a potent antioxidant that helps neutralize these free radicals, preventing cellular damage and degeneration. Turmeric is also linked to reducing oxidative stress on vascular tissues that can increase risk of chronic disease. Turmeric may reverse steps in the heart disease process by improving the function of the lining of your blood vessels. Hence, this helps regulate your blood pressure, blood clotting and other factors vital to heart health. Also, preliminary studies show that curcumin may reduce the number of heart attacks bypass patients had after surgery. Turmeric has been proven to help lower brain disease risk. Evidence shows that curcumin may affect brain function and the development of dementia. Furthermore, curcumin may be effective in delaying or reversing brain diseases and age-related decreases in brain function. This happens by triggering a growth hormone in the brain that helps spur new brain cell growth. And, there are early signs that turmeric can even improve your memory. Turmeric has long been used to help soothe stomach pain, relieve constipation and control irritable bowel syndrome. More so, its anti-inflammatory properties can lower your chance of developing ulcers and remove digestive system irritation. You can generally find turmeric in the spice aisle of your local grocery store. Turmeric, when taken orally or applied to the skin, is considered safe for health purposes. Taking turmeric with black pepper enhances absorption. Before taking turmeric or changing your diet, we recommend reaching out to a doctor. Visit mercy. com to find a physician near you today. For other ways to fuel your health, check out foods full of heart-healthy fats. As always, you should consult your doctor before making any major changes to your diet. com or call to find a doctor near you today. Healthy Living Top 5 Health Benefits of Turmeric Jan 22 Anti-Inflammatory Properties If you want to control inflammation, turmeric can do the trick. Antioxidants Oxidative damage is thought to be a trigger for aging and a variety of diseases. Lowered Risk of Heart Disease Turmeric may reverse steps in the heart disease process by improving the function of the lining of your blood vessels. Prevention of Brain Disease Turmeric has been proven to help lower brain disease risk. Increased Digestive Health Turmeric has long been used to help soothe stomach pain, relieve constipation and control irritable bowel syndrome. Where can you find turmeric? Related Posts Sore Throat vs. When to Keep a Sick Kid Home from School. Can You Get a Pap Smear on Your Period? Firestein Answers This Question and More. Sue I have A-fib and take Xarelto. Is it safe for me to take turmeric? |
| Plant Description | Clinical utility of curcumin extract. Altern Ther Health Med. Baum L, Cheung SK, Mok VC, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. Blumenthal M, Goldberg A, Brinckmann J. Herbal Medicine: Expanded Commission E Monographs. Newton, MA: Integrative Medicine Communications; Bolognia JL, Jorizzo JL, Schaffer JV, eds. Philadelphia, PA: Elsevier Saunders; Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and Liver Cancer: A Review. Curr Pharm Biotechnol. Davis JM, Murphy EA, Carmichael MD, et al. Curcumin effects on inflammation and performance recovery following eccentric exercise-induced muscle damage. Am J Physiol Regul Integr Comp Physiol. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Dorai T, Gehani N, Katz A. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol. Funk JL, Frye JB, Oyarzo JN, et al. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum. Gautam SC, Gao X, Dulchavsky S. Immunodilation by curcumin. Gescher AJ, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. Handler N, Jaeger W, Puschacher H, Leisser K, Erker T. Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 COX-1 inhibitors. Chem Pharm Bull Tokyo. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. Jagetia GC, Aggarwal BB. J Clin Immunol. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett. Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys. Kim DS, Kim JY, Han Y. Curcuminoids in neurodegenerative diseases. Recent Pat CNS Drug Discov. Kim MS, Kang HJ, Moon A. Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res. Krishnaswamy K. Traditional Indian spices and their health significance. Asia Pac J Clin Nutr. Nagaraju GP, Aliya S, Zafar SF, Basha R, Diaz R, El-Rayes BF. The impact of curcumin on breast cancer. Integr Biol Camb. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem. Phan TT, See P, Lee ST, Chan SY. Protective effects of curcumin against oxidative damage on skin cells in vitro: its implication for wound healing. J Trauma. Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of dietary curcumin on glutathione S -Transferase and Malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Shehzad A, Khan S, Shehzad O, Lee YS. Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today Barc. Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Su CC, Lin JG, Li TM, et al. Anticancer Res. Suryanarayana P, Satyanarayana A, Balakrishna N, Kumar PU, Reddy GB. Effect of turmeric and curcumin on oxidative stress and antioxidant enzymes in streptozotocin-induced diabetic rat. Med Sci Monit. Vaughn AR, Branum A, Sivamani RK. Effects of turmeric Curcuma longa on skin health: A systematic review of the clinical evidence. Phytother Res. White B, Judkins DZ. Clinical Inquiry. Does turmeric relieve inflammatory conditions? J Fam Pract. Zafir A, Banu N. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol. Share Facebook Twitter Linkedin Email Home Health Library. Turmeric Curcuma longa. Plant Description A relative of ginger, turmeric is a perennial plant that grows 5 to 6 feet high in the tropical regions of Southern Asia, with trumpet-shaped, dull yellow flowers. Allicin is responsible for most of the health benefits you reap from garlic. If you already have high cholesterol, supplementing with garlic could reduce your LDL and total cholesterol by as much as 10 to 15 percent. Incorporating more garlic into your diet can be easy! Try adding chopped cloves to sautéed greens such as broccoli, kale, and spinach. Potatoes can be roasted with whole garlic cloves and then sprinkled with your favorite seasoning, and crushed or chopped garlic goes great with almost all Italian dishes. From reducing blood pressure to lowering levels of bad cholesterol, the health advantages of adding more garlic to your diet can aid in the prevention of heart disease and heart-related conditions, such as a heart attack. Native to India and Southeast Asia, turmeric is a bright yellow spice that has long been used for both medicinal purposes and flavoring food. Studies have shown that curcumin serves as a powerful antioxidant and anti-inflammatory. Since inflammation is a strong component in so many conditions, especially heart disease, the anti-inflammatory properties of curcumin make it a great addition to any heart healthy diet. Luckily, turmeric pairs great with many dishes! Add it to scrambled eggs, roasted veggies, rice, sautéed greens, soup, and more. You can also get creative by blending the spice into smoothies, or simmering with coconut milk for a homemade tea. |
0 thoughts on “Turmeric for heart health”